🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  2. Zometa 4 mg/100 ml solution for infusion

    Ningbo Cancer Hospital

    High grade osteosarcoma

    phase 3 small molecule active

    1 trial

  3. Zometa 4 mg/100 ml solution for infusion, XGEVA 120 mg solution for injection in pre-filled syringe

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy

    phase 3 small molecule active

    1 trial

  4. Zydelig 100 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Zydelig 150 mg film-coated tablets, Truxima 500 mg concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Zydelig 100 mg film-coated tablets, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer I

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  5. apomorphine infusion

    SUPERNUS PHARMACEUTICALS, INC.

    Idiopathic Parkinson's Disease

    phase 3 small molecule active

    1 trial

  6. commercially available saline solution for infusion, Amlenetug 53 mg/ml solution for infusion

    H. Lundbeck A/S

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  7. donor lymphocyte infusion

    The First People's Hospital of Lianyungang

    Minimal Residual Disease

    phase 3 mab completed

    1 trial

  8. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  9. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  10. mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab

    BeiGene

    Locally advanced, unresectable, or metastatic non small cell lung cancer

    phase 3 small molecule active

    1 trial

  12. relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.

    CORCEPT THERAPEUTICS INC

    Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    phase 3 small molecule active

    1 trial

  13. volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  14. -, CYCLOPHOSPHAMIDE, Cesnicabtagene autoleucel, PARACETAMOL, FLUDARABINE, LENALIDOMIDE, RoActemra 20 mg/mL concentrate for solution for infusion

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial

  15. -, Raludotatug Deruxtecan, MK-4830, MK-1308A, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib, MK-4280A, DEXAMETHASONE , APREPITANT

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  16. 0.9% sodium chloride aqueous solution for IV infusion

    Chiesi Farmaceutici S.p.A

    Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  17. 00 mg/mL Concentrate for solution for infusion, VHB937

    Novartis Pharmaceuticals

    Alzheimer’s disease

    phase 2 small molecule active

    1 trial

  18. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  19. 89Zr-Trastuzumab_IJB, Herceptin 150 mg powder for concentrate for solution for infusion, TRASTUZUMAB EMTANSINE

    The George Institute

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  20. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  21. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Ningbo Cancer Hospital

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  22. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  23. ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  24. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources